Gruppo Italiano Malattie EMatologiche dell'Adulto
143
20
31
60
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
6.3%
9 terminated/withdrawn out of 143 trials
87.0%
+0.5% vs industry average
13%
18 trials in Phase 3/4
17%
10 of 60 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (143)
Infection Surveillance of R/R Multiple Myeloma Patients Treated With Elranatamab as Clinical Practice in Italy
Role: lead
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Role: collaborator
Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL
Role: lead
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Role: collaborator
Role of Adrenomedullin in Leukemic Endosteal/Vascular Niches
Role: lead
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
Role: lead
Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program
Role: lead
Evaluation of the Efficacy of Ponatinib in Ph+ ALL in the Real-world
Role: lead
Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma
Role: collaborator
Momelotinib Effectiveness in Myelofibrosis
Role: lead
Patient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).
Role: lead
Myeloproliferative Neoplasms (MPN) and COVID-19
Role: collaborator
Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients
Role: lead
Identification of BCR::ABL1 Mutations by Digital PCR in CML
Role: lead
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
Role: lead
Observational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTions
Role: lead
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome
Role: lead
PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML
Role: lead
Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96
Role: lead
Clinical Decision-making, Prognosis, Quality of Life and Satisfaction in Relapsed/Refractory Multiple Myeloma
Role: lead